EI
DNTH icon

Ellevest Inc’s Dianthus Therapeutics DNTH Stock Holding History

Ellevest Inc’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed – – 1456
2022
Q1 		$0 Buy
+3
New +$164 ﹤0.01% 1468
2021
Q3 		– Sell
-3
Closed – – 1445
2021
Q2 		$0 Buy
3
+2
+200% +$367 ﹤0.01% 1301
2021
Q1 		$0 Hold
1
– – ﹤0.01% 1278
2020
Q4 		$0 Sell
1
-4
-80% -$454 ﹤0.01% 1227
2020
Q3 		$1K Buy
+5
New +$592 ﹤0.01% 989

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ellevest Inc's DNTH Position: Q2 2022 in Review

Ellevest Inc sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 3 shares.

Ellevest Inc first reported a position in DNTH in Q3 2020 and held it in 5 quarters. The position peaked at $1K in Q3 2020. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

  • Ellevest Inc reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ellevest Inc sold 3 Dianthus Therapeutics shares in Q2 2022.
  • Ellevest Inc first reported a position in Dianthus Therapeutics in Q3 2020 and held it in 5 quarters.
  • Ellevest Inc's Dianthus Therapeutics position peaked at $1K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Ellevest Inc's 13F filing for Q2 2022, filed 18 Jul 2022.